System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Elena Verzoni is an expert in Oncology at Fondazione IRCCS Istituto Nazionale dei Tumori (Italy). As of October 2026, ScienceLeadR ranks Elena Verzoni in the top 1% of experts worldwide for Kidney Neoplasms, Urologic Neoplasms and Carcinoma. Elena Verzoni has authored 321 publications, the most recent in 2026, and is an investigator in 28 clinical trials, 10 of them ongoing. SLR score: 1,629 (community average: 125). How the SLR is computed.

LeadR Profile

Elena Verzoni Fondazione IRCCS Istituto Nazionale dei Tumori Italy
1 629 ScienceLeadR Reputation 1629

Unlock

Register Login
Network Map

Oncology

Subspecialties: Urology - Pharmacy - Immunology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2003 - 2026
Source: PubMed

Fondazione IRCCS Istituto Nazionale dei Tumori

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 321

Citations

Citations: 3 608 1st author: 32 Last author: 38 Unique author: 0

Main journals

J Clin Oncol 74
Ann Oncol 42
Tumori 21
Clin Genitourin Cancer 16
Expert Rev Anticancer Ther 11

Best Journals

J Clin Oncol 45
Ann Oncol 18
Lancet Oncol 5

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial.
PMID 42586114 — cells, progression-free survival, disease progression, carcinoma, renal cell, drug-related side effects and adverse reactions, therapeutics		Lancet Top journal20263
Reducing the burden of active surveillance monitoring examinations in prostate cancer: Insights from real-world data to inform clinical practice.
PMID 42639746 — neoplasms, pathology, prostate, biopsy, prostatic neoplasms, prognosis		Tumori20260
Impact of PSA Nadir on Outcomes in Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review and Reconstructed Individual Patient Data Meta-analysis.
PMID 42568016 — progression-free survival, docetaxel, neoplasms, prostate, hormones, prostatic neoplasms, therapeutics		Target Oncol20260
Nectin-4 and Trop-2 expression in collecting duct carcinoma: new promising therapeutic targets.
PMID 42526179 — nectins, neoplasms, carcinoma, renal cell, therapeutics		ESMO Open20261
Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer.
PMID 42485627 — urinary bladder, urinary bladder neoplasms, disease-free survival, muscles, incidence, neoplasms, drug therapy, cystectomy, drug-related side effects and adverse reactions, therapeutics, chemotherapy		N Engl J Med Top journal202619

Clinical Studies 28

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1

By phase:

Phase 3 14
Phase 2 7
Phase 1/Phase 2 4
N/A 3

By status:

Active not recruiting 9
Completed 8
Recruiting 7
Terminated 2
Unknown 2

By type:

Interventional 25
Observational 3

By Monocentric/Multicentric:

monocentric 7
multicentric2to4 1
multicentric5to9 1
multicentricup10 19

Main Topics

Ongoing Clinical Trials

10 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A clinical trial to learn about the effects of AMO959 given with AAA617 and an androgen receptor pathway inhibitor (ARPI) in adults with PSMA positive prostate cancer that has spread to other parts of the body pathway inhibitor (ARPI) in adults with PSMA positive prostate cancer that has spread to other parts of the body
2025-521859-23-00 — protein kinases, androgens, receptors, androgen, neoplasms, multiple chronic conditions, prostate, protein kinase inhibitors, prostatic neoplasms, castration, dna		Phase 1/Phase 2Recruiting2026
Phase 3 Study of Xaluritamig Plus Abiraterone vs Investigator s Choice in Chemotherapy na ve Metastatic Castration resistant Prostate Cancer
2025-520555-89-00 — neoplasms, prostate, drug therapy, prostatic neoplasms, castration, therapeutics, chemotherapy		Phase 3Recruiting2025
A Phase 1 2 Open Label Rolling Arm Umbrella Platform Study of Investigational Agents With or Without Pembrolizumab in Participants with PD 1 L1 Refractory Locally Advanced or Metastatic Urothelial Carcinoma (KEYMAKER U04) Substudy 04A
2023-506384-34-00 — response evaluation criteria in solid tumors, carcinoma		Phase 1/Phase 2Recruiting2025
A clinical study of ifinatamab deruxtecan to treat metastatic prostate cancer (MK 2400 01A)
2024-516036-94-00 — safety, neoplasms, prostate, prostatic neoplasms, castration, therapeutics		Phase 1/Phase 2Recruiting2025
A clinical trial to learn about the effects of DZR123 and JSB462 given together in men with advanced prostate cancer that has stopped responding to other treatments
2025-521880-10-00 — safety, neoplasms, prostate, prostatic neoplasms, therapeutics, men		Phase 1/Phase 2Recruiting2026

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS